Authors:
Sushma Jonna, Rebecca Feldman, Sai-Hong Ignatius Ou, Misako Nagasaka, Jeffrey Swensen, Wolfgang Michael Korn, Hossein Borghaei, Ari M. Vanderwalde, Gilberto Lopes, Jorge J. Nieva, Alexander I. Spira, Edward S. Kim, Stephen V. Liu
Conclusions:
In a much larger sample, the incidence of NRG1 fusions across tumor types remained 0.2% (82/44,570). • There is notable variation within NRG1 fusions across tumors. The biologic and clinical significance of this heterogeneity is unclear. • Therapeutic studies should incorporate NRG1 fusion variants in any efficacy results.
Download PublicationCookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |